Company: CRNX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001658247-25-000019
Chunk: 83

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 83
---
 There were no revenues for the three months ended September 30, 2024.

Research and development expenses.    The increase of $28.6 million and $73.4 million in research and development expenses during the three and nine months ended September 30, 2025, respectively, compared to the prior year periods was primarily due to an increase in headcount, manufacturing activities and increased clinical costs driven by the advancement of our clinical programs and the advancement of our preclinical portfolio, as outlined below.

23

Table of Contents

The following table summarizes our primary external and internal research and development expenses for the three and nine months ended September 30, 2025 and 2024 (in thousands):

Three months ended September 30,$Change%ChangeNine months ended September 30,$Change%Change2025202420252024External research and development expenses:Clinical trials$17,312 $10,131 $7,181 71 %$44,139 $29,673 $14,466 49 %Contract manufacturing10,133 7,104 3,029 43 %26,307 19,078 7,229 38 %Preclinical studies4,664 4,213 451 11 %10,574 8,329 2,245 27 %Outside services13,991 8,463 5,528 65 %36,396 24,548 11,848 48 %Other external research and development8 11 (3)(27)%38 24 14 58 %Total external research and development expenses46,108 29,922 16,186 54 %117,454 81,652 35,802 44 %Internal expenses:Personnel expenses26,062 17,617 8,445 48 %76,827 50,489 26,338 52 %Stock-based compensation13,003 10,556 2,447 23 %37,921 29,612 8,309 28 %Facilities and related3,242 2,847 395 14 %9,244 8,518 726 9 %Other internal research and development2,049 963 1,086 113 %5,559 3,319 2,240 67 %Total internal research and development expenses44,356 31